call. quarter everyone. us Thank fourth Movano earnings Welcome, you joining for Health's from
potential. given remarkable excited progress, approaching more far quickly I'm anniversary We are future and our company. the our second our company's about how traded as we've come, publicly It's even
and should more more belief devices, is health forging $XX a opportunity products believe conservatively wearables territory accurate. that by at worth of accessible, the more market a creating health U.S. driven category, fast-growing alone. medtech and intersection We're by the standard in We're positioned developing consumer billion new we actionable the for our be data new
briefly year this that be part and into commercial highlight of our including for insight smart last hearing demand and milestones as progress Evie the some potential the quarter over call for the to of made in and launch the significant key of wanted today's give we the We've Ring, early ring, about the following. prepare preparedness more I you'll
which completed to our well Evie Ahead in in pivotal the and successfully launch, We consumer the was hypoxia we within CES study, announced Ring having Evie planned resulted FDA be accuracy the Ring January, and summer incredibly of standards. at continues the and reception media the positive.
medical continued global to programs leading are a commenced with the and companies. a of with We Evie evaluate beta second the partners Ring, global additional among partners company solution, slate new announced four we and in first round two our program our previously beta apparel of today, given strong announced athletic which interest device
with make We pressure RF blood our which and proprietary glucose engine also to is initiatives. continue technology, our the progress driving
We glucose studies will be the the chip time. using conducting for blood technology and single clinical first imminently pressure
to achieve Health company. a mile level trust not going separates that a What from offered the by building is company as the wearables. competition credibility medical other we're of and device We're consumer Movano extra our
We team clinical product processes run and appropriate quality, design have quality ensure followed. and are our a system by to regulatory testing management
FDA employing the to assure of quality to a as are trials systems We run security. multibillion-dollar compliant regulations data HIPAA of formal as compliant a maintain the clinical mandated medical manufacturer services contract FDA and also we using device. by ring We're the
consensus year. hypoxia are QX standard file of data on the track we ring's XXX(k) of in in margin pivotal an completing error, a reference spring the for Evie's as study's to medical our devices, device for last X.X% approximate this Evie after first the with SpOX the successful comparing of data, accuracy heart FDA rate from SpOX. And X% In company, and overall a resulted of well trial data below
monitor Evie's had square the study, also heart of FDA's error the is during line root requirements. Additionally, per approximately mean in with rate minute, X which beats
Now gathering the to are the timeframe, submission, XXX(k) small process studies. the of with submitted that benchmarks to the the achieved the expect the from FDA required FDA four data accuracy FDA, The spring months. is have submission by take the we task. for about we three beyond documentation documents we requires Once needed is hundreds which no in our
of leverage allow device. wellness to may medical If we a device which which advantages. prepared our dovetail the believe will launch launch competitive an with higher FDA, the we're Evie and our of the as is decision not, standard the Evie to timing a The highlight us as to from summer opportunity accuracy then product one delivers, as this the clearance FDA of launch
comprehensive and FDA us more. and give Our end-to-end are look our wearables health medical consumer their to business direct payers to healthcare accelerating as the other business With pursuit address for pharmaceutical, both needs being of enterprises well such a as unique consumer solutions that clearances positions at designed well opportunities. of demand and data, customers to as device,
game in of offers is of levels over that ability to XX a and with wearable For the oxygen those the people oxygen company various on be and her U.S., example, affected. monitors beta-two technology our could the impact a throughout a daily conditions partners leading that respiratory activities solutions one day changer in-home or use. one's for million the requirements solution there for medical offer global his pulmonary Currently are
Evie partnerships medical opportunity outcomes, and variety improve of for patient that and innovation expectation specific growth. product with highlight act driver a of is as a Our our conditions, will beta monitor programs the Ring to the integrated
Evie company, a launch pre- point be the us. and will for first commercial Ring from you As inflection will for a planned a know, summer, product take major revenue-generating representing to us our this
of outstanding the Consumer need, major validated this January. the uniquely of a the ring Evie the in first As was unveiling medical-grade unmet at Show designed and smart by first believe women, week ring the to Electronics we on for the delivers reception
leading update Tyla on our now you to marketing our turn the me to Marketing Let launch. call strategy up the Evie Chief to over Bucher, Officer,
